{"version":"1.0","provider_name":"Indonesia Tribune","provider_url":"https:\/\/indonesiatribune.com","author_name":"admin","author_url":"https:\/\/indonesiatribune.com\/author\/admin\/","title":"Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough - Indonesia Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"IyLmac6WNZ\"><a href=\"https:\/\/indonesiatribune.com\/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough\/\">Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/indonesiatribune.com\/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough\/embed\/#?secret=IyLmac6WNZ\" width=\"600\" height=\"338\" title=\"&#8220;Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough&#8221; &#8212; Indonesia Tribune\" data-secret=\"IyLmac6WNZ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) \u2014 Algernon Pharmaceuticals Inc.\u00a0(the \u201cCompany\u201d or \u201cAlgernon\u201d) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce positive topline data showing that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (\u201cIfenprodil\u201d) for [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/OdNuSuYlKBBocKQ76IouxtBr4UQ3G3sI0Lui56XGZz_70yakoNbhvde3BeX8ys6RDMSa0QhHVq-v2DpM6z8icLyygL6LVIIHQGPak90c1U9MGqqdAXLn8KIgbvNLKXRA=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwMDkxNyM1MDQzMDAyIzIwOTIzNjc="}